Acro Biomedical Co., Ltd. (ACBM)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2022 | 25.71 Thousand USD | -49.0% |
| 2021 | 50.43 Thousand USD | 105.84% |
| 2020 | 24.5 Thousand USD | -47.1% |
| 2019 | 46.31 Thousand USD | -67.19% |
| 2018 | 141.13 Thousand USD | 287.96% |
| 2017 | 36.37 Thousand USD | 263.79% |
| 2016 | 10 Thousand USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 Q2 | 12.98 Thousand USD | -33.0% |
| 2023 Q1 | 19.38 Thousand USD | -24.63% |
| 2022 Q2 | 38.19 Thousand USD | -13.86% |
| 2022 FY | 25.71 Thousand USD | -49.0% |
| 2022 Q1 | 44.34 Thousand USD | -12.07% |
| 2022 Q4 | 25.71 Thousand USD | -19.6% |
| 2022 Q3 | 31.99 Thousand USD | -16.25% |
| 2021 Q2 | 12.15 Thousand USD | -33.79% |
| 2021 Q4 | 50.43 Thousand USD | 756.52% |
| 2021 Q3 | 5888.00 USD | -51.56% |
| 2021 Q1 | 18.35 Thousand USD | -25.07% |
| 2021 FY | 50.43 Thousand USD | 105.84% |
| 2020 Q4 | 24.5 Thousand USD | -19.88% |
| 2020 FY | 24.5 Thousand USD | -47.1% |
| 2020 Q3 | 30.58 Thousand USD | -16.45% |
| 2020 Q2 | 36.6 Thousand USD | -14.01% |
| 2020 Q1 | 42.56 Thousand USD | -8.09% |
| 2019 Q4 | 46.31 Thousand USD | -55.21% |
| 2019 Q1 | 18.4 Thousand USD | 463.56% |
| 2019 Q3 | 103.4 Thousand USD | 0.0% |
| 2019 FY | 46.31 Thousand USD | -67.19% |
| 2019 Q2 | 103.4 Thousand USD | 461.78% |
| 2018 FY | 141.13 Thousand USD | 287.96% |
| 2018 Q4 | 3266.00 USD | -97.69% |
| 2018 Q3 | 141.13 Thousand USD | 0.5% |
| 2018 Q2 | 140.43 Thousand USD | 47.37% |
| 2018 Q1 | 95.29 Thousand USD | 130.34% |
| 2017 Q2 | 26.26 Thousand USD | 201.54% |
| 2017 FY | 36.37 Thousand USD | 263.79% |
| 2017 Q4 | 41.37 Thousand USD | 13.72% |
| 2017 Q3 | 36.37 Thousand USD | 38.51% |
| 2017 Q1 | 8710.00 USD | -12.9% |
| 2016 FY | 10 Thousand USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2016 Q3 | 10 Thousand USD | 0.0% |
| 2016 Q4 | 10 Thousand USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 99.938% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 99.376% |
| SQZ Biotechnologies Company | 27.47 Million USD | 99.906% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 99.941% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 99.914% |
| Mesoblast Limited | 118.7 Million USD | 99.978% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | 97.288% |
| Genus plc | 233.1 Million USD | 99.989% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | 99.122% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 98.086% |
| Marizyme, Inc. | 18.71 Million USD | 99.863% |
| ContraFect Corporation | 2.88 Million USD | 99.107% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | 96.571% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | 81.017% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | 98.222% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | 98.894% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 99.545% |
| MultiCell Technologies, Inc. | 202.58 USD | -12595.725% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 99.955% |
| EV Biologics, Inc. | 1.49 Million USD | 98.279% |
| Q BioMed Inc. | 4.1 Million USD | 99.374% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 99.922% |
| Neon Bloom, Inc. | 630.07 Thousand USD | 95.918% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | 97.906% |
| Biomind Labs Inc. | 735.54 Thousand USD | 96.503% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 99.985% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 99.802% |
| Skye Bioscience, Inc. | 4.61 Million USD | 99.443% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | 97.104% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | 81.826% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 99.562% |
| IMV Inc. | 28.88 Million USD | 99.911% |
| Curative Biotechnology, Inc. | 2.25 Million USD | 98.861% |
| GB Sciences, Inc. | 1.75 Million USD | 98.538% |
| Alpha Cognition Inc. | 1.22 Million USD | 97.893% |
| HST Global, Inc. | 98.31 Thousand USD | 73.841% |
| CSL Limited | 12.18 Billion USD | 100.0% |
| Halberd Corporation | 150 Thousand USD | 82.854% |
| Enzolytics Inc. | 996.33 Thousand USD | 97.419% |
| Resverlogix Corp. | 6.49 Million USD | 99.604% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | 94.614% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | 89.937% |
| argenx SE | 20 Million USD | 99.871% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 99.944% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 99.051% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -151.531% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.994% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | 87.18% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | 98.927% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | 88.783% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 99.962% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | 99.15% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 92.85% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 99.873% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | 82.699% |
| BioStem Technologies, Inc. | 4.71 Million USD | 99.454% |
| ONE Bio Corp. | 19.71 Million USD | 99.87% |
| Reve Technologies, Inc. | 250.18 Thousand USD | 89.72% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | 89.659% |
| Agentix Corp. | 50 Thousand USD | 48.562% |
| LadRx Corporation | 33.6 Thousand USD | 23.469% |
| Cell Source, Inc. | 9.25 Million USD | 99.722% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | 96.599% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | 96.599% |
| NovAccess Global Inc. | 2.19 Million USD | 98.831% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 99.636% |
| Itoco Inc. | 228.37 Thousand USD | 88.738% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | 87.809% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 99.484% |
| Kadimastem Ltd | 891.22 Thousand USD | 97.114% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 93.6% |
| CytoDyn Inc. | 30.07 Million USD | 99.914% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | 94.689% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | 92.69% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 99.671% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | 79.005% |
| Rebus Holdings, Inc. | 310 Thousand USD | 91.704% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 99.457% |
| International Stem Cell Corporation | 4.17 Million USD | 99.384% |
| Bioxytran, Inc. | 1.92 Million USD | 98.664% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 58.792% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 98.821% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 99.691% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 99.7% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | 98.347% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | 90.403% |
| Neutra Corp. | 54.15 Thousand USD | 52.509% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | 98.595% |
| PureTech Health plc | 25.51 Million USD | 99.899% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | 97.899% |
| IXICO plc | 472.02 Thousand USD | 94.551% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 99.834% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 99.959% |
| CSL Limited | 12.18 Billion USD | 100.0% |
| Cellectis S.A. | 92.77 Million USD | 99.972% |